Literature DB >> 6967912

Effect of thymopoietin pentapeptide (TP5) on autoimmunity. I. TP5 suppression of induced erythrocyte autoantibodies in C3H mice.

C Y Lau, J A Freestone, G Goldstein.   

Abstract

C3H mice (young and old), when immunized with the cross-reacting rat erythrocytes, produced erythrocyte autoantibodies that usually persisted for more than 10 weeks. I.P. injection of thymopoietin pentapeptide (TP5) once or thrice weekly accelerated the loss of erythrocyte autoantibodies 7 weeks after immunization; 10 ng of TP5 was the optimal dose. The rat agglutinin responses of these immunized mice were unaffected by TP5 during the whole period of study. Spleen cells from rat erythrocyte-immunized mice, when transferred to syngeneic recipients undergoing similar immunization schedules, delayed the appearance of erythrocyte autoantibodies in the recipients. A greater delay was observed when spleen cells were taken from mice that had also received TP5 treatment.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6967912

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Functional anatomy of the thymic microenvironment.

Authors:  M D Kendall
Journal:  J Anat       Date:  1991-08       Impact factor: 2.610

2.  Thymopentin: stability considerations and potency by various routes of administration.

Authors:  T K Audhya; G Goldstein
Journal:  Surv Immunol Res       Date:  1985

3.  Prevention of recurrences in frequently relapsing herpes labialis with thymopentin. A randomized double-blind placebo-controlled multicenter study.

Authors:  K Bolla; D Djawari; E M Kokoschka; J Petres; S Lidén; R Gonseth; P Amblard; M G Bernengo; J J Bonerandi; A Claudy
Journal:  Surv Immunol Res       Date:  1985

4.  In vitro influence of thymopentin on proliferative responses and phytohemagglutinin-induced interleukin 2 production in normal human lymphocyte cultures.

Authors:  J Duchateau; G Servais; R Cooman; H Collet; K Bolla
Journal:  Surv Immunol Res       Date:  1985

5.  Rationale for thymopentin as therapeutic agent in rheumatoid arthritis.

Authors:  P Franchimont; K Bolla
Journal:  Surv Immunol Res       Date:  1985

6.  Contrasting biological activities of thymopoietin and splenin, two closely related polypeptide products of thymus and spleen.

Authors:  T Audhya; M P Scheid; G Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

Review 7.  Thymopoietin to thymopentin: experimental studies.

Authors:  G Goldstein; T K Audhya
Journal:  Surv Immunol Res       Date:  1985

Review 8.  Thymopentin and splenopentin as immunomodulators. Current status.

Authors:  V K Singh; S Biswas; K B Mathur; W Haq; S K Garg; S S Agarwal
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.